Dawson James analyst Jason Kolbert believes Pluristem "has given itself the best possible chance for success" in Critical Limb Ischemia, or CLI, which the company is currently investigating in a Phase 3 trial. He also notes that Marwood group estimates that the incidence of CLI in the U.S. is rising, with between 2 and 3 million CLI patients in the U.S. and 500,000 to 600,000 new cases per year. The analyst, who concludes that Pluristem could have "a blockbuster new therapy in CLI" with its PLX-PAD regenerative cell therapy, keeps a Buy rating and $12 price target on Pluristem shares.